The genetic architecture of multiple myeloma

Advances in Hematology

Volumn 2014, Issue , 2014, Pages

  Prideaux, Steven M ^a   Conway O'Brien, Emma ^a   Chevassut, Timothy J ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; IMMUNOGLOBULIN HEAVY CHAIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE;

ALLELE; ANEMIA; BONE DISEASE; BONE MARROW; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMOSOME 11; CHROMOSOME 14; CHROMOSOME 15; CHROMOSOME 19; CHROMOSOME 21; CHROMOSOME 3; CHROMOSOME 5; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; COPY NUMBER VARIATION; DISEASE COURSE; DNA METHYLATION; DNA REPAIR; EPIGENETICS; HUMAN; HYPERCALCEMIA; MICROENVIRONMENT; MULTIPLE MYELOMA; MUTAGENIC ACTIVITY; MYELOMA; NONHUMAN; PLASMA CELL; PROGNOSIS; PROTEIN HOMEOSTASIS; REVIEW; RNA EDITING; TRISOMY;

EID: 84899512245     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2014/864058     Document Type: Review

References (137)

1. Kyle R. A., Durie B. G., Rajkumar S. V., Landgren O., Blade J., Merlini G., Kröger N., Einsele H., Vesole D. H., Dimopoulos M., San Miguel J., Avet-Loiseau H., Hajek R., Chen W. M., Anderson K. C., Ludwig H., Sonneveld P., Pavlovsky S., Palumbo A., Richardson P. G., Barlogie B., Greipp P., Vescio R., Turesson I., Westin J., Boccadoro M., International Myeloma Working Group I. M. W. G., Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010 24 6 1121 1127 2-s2.0-77954610729
2. Kyle R. A., Therneau T. M., Rajkumar S. V., Larson D. R., Plevak M. F., Offord J. R., Dispenzieri A., Katzmann J. A., Melton L. J. III, Prevalence of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine 2006 354 13 1362 1369 2-s2.0-33645416095 10.1056/NEJMoa054494
3. Kyle R. A., Therneau T. M., Vincent Rajkumar S., Offord J. R., Larson D. R., Plevak M. F., Joseph Melton L. III, A long-term study of prognosis in monoclonal gammopathy of undetermined significance. The New England Journal of Medicine 2002 346 8 564 569 2-s2.0-0037148921 10.1056/NEJMoa01133202 (Pubitemid 34438817)
4. Kyle R. A., Remstein E. D., Therneau T. M., Dispenzieri A., Kurtin P. J., Hodnefield J. M., Larson D. R., Plevak M. F., Jelinek D. F., Fonseca R., Melton L. J. III, Rajkumar S. V., Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. The New England Journal of Medicine 2007 356 25 2582 2590 2-s2.0-34250694807 10.1056/NEJMoa070389 (Pubitemid 46961003)
5. Chapman M. A., Lawrence M. S., Keats J. J., Cibulskis K., Sougnez C., Schinzel A. C., Harview C. L., Brunet J.-P., Ahmann G. J., Adli M., Anderson K. C., Ardlie K. G., Auclair D., Baker A., Bergsagel P. L., Bernstein B. E., Drier Y., Fonseca R., Gabriel S. B., Hofmeister C. C., Jagannath S., Jakubowiak A. J., Krishnan A., Levy J., Liefeld T., Lonial S., Mahan S., Mfuko B., Monti S., Perkins L. M., Onofrio R., Pugh T. J., Rajkumar S. V., Ramos A. H., Siegel D. S., Sivachenko A., Stewart A. K., Trudel S., Vij R., Voet D., Winckler W., Zimmerman T., Carpten J., Trent J., Hahn W. C., Garraway L. A., Meyerson M., Lander E. S., Getz G., Golub T. R., Initial genome sequencing and analysis of multiple myeloma. Nature 2011 471 7339 467 472 2-s2.0-79951494668 10.1038/nature09837
6. Egan J. B., Shi C. X., Tembe W., Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012 120 5 1060 1066
7. Anderson K., Lutz C., van Delft F. W., Bateman C. M., Guo Y., Colman S. M., Kempski H., Moorman A. V., Titley I., Swansbury J., Kearney L., Enver T., Greaves M., Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011 469 7330 356 361 2-s2.0-78751644099 10.1038/nature09650
8. Morgan G. J., Walker B. A., Davies F. E., The genetic architecture of multiple myeloma. Nature Reviews Cancer 2012 12 5 335 348 2-s2.0-84860219443 10.1038/nrc3257
9. Kuehl W. M., Bergsagel P. L., Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology 2005 346 352 2-s2.0-33745259948
10. Bergsagel P. L., Kuehl W. M., Molecular pathogenesis and a consequent classification of multiple myeloma. Journal of Clinical Oncology 2005 23 26 6333 6338 2-s2.0-27244445489 10.1200/JCO.2005.05.021 (Pubitemid 46218843)
11. Smadja N.-V., Fruchart C., Isnard F., Louvet C., Dutel J.-L., Cheron N., Grange M.-J., Monconduit M., Bastard C., Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998 12 6 960 969 2-s2.0-0031861960 (Pubitemid 28287221)
12. Gould J., Alexanian R., Goodacre A., Pathak S., Hecht B., Barlogie B., Plasma cell karyotype in multiple myeloma. Blood 1988 71 2 453 456 2-s2.0-0023853845 (Pubitemid 18089536)
13. Sawyer J. R., Waldron J. A., Jagannath S., Barlogie B., Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics and Cytogenetics 1995 82 1 41 49 2-s2.0-0029162938 10.1016/0165-4608(94)00284-I
14. Smadja N. V., Bastard C., Brigaudeau C., Leroux D., Fruchart C., Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001 98 7 2229 2238 2-s2.0-0035496928 10.1182/blood.V98.7.2229
15. Dewald G. W., Kyle R. A., Hicks G. A., Greipp P. R., The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985 66 2 380 390 2-s2.0-0021792205 (Pubitemid 15007030)
16. Bergsagel P. L., Kuehl W. M., Zhan F., Sawyer J., Barlogie B., Shaughnessy Jr. J., Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005 106 1 296 303 2-s2.0-22044440425 10.1182/blood-2005-01-0034 (Pubitemid 40967205)
17. Kuehl W. M., Bergsagel P. L., Molecular pathogenesis of multiple myeloma and its premalignant precursor. Journal of Clinical Investigation 2012 122 10 3456 3463
18. Neri P., Ren L., Azab A. K., Brentnall M., Gratton K., Klimowicz A. C., Lin C., Duggan P., Tassone P., Mansoor A., Stewart D. A., Boise L. H., Ghobrial I. M., Bahlis N. J., Integrin β 7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 2011 117 23 6202 6213 2-s2.0-79959417349 10.1182/blood-2010-06-292243
19. Brennan S. K., Wang Q., Tressler R., Harley C., Go N., Bassett E., Huff C. A., Jones R. J., Matsui W., Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS ONE 2010 5 9 2-s2.0-77958584577 10.1371/journal.pone.0012487 12487
20. Kuehl W. M., Bergsagel P. L., Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer 2002 2 3 175 187 2-s2.0-0036512435 (Pubitemid 37328787)
21. Hideshima T., Mitsiades C., Tonon G., Richardson P. G., Anderson K. C., Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer 2007 7 8 585 598 2-s2.0-34547106018 10.1038/nrc2189 (Pubitemid 47106630)
22. Roodman G. D., Targeting the bone microenvironment in multiple myeloma. Journal of Bone and Mineral Metabolism 2010 28 3 244 250 2-s2.0-77956030798 10.1007/s00774-009-0154-7
23. Rasmussen T., Haaber J., Dahl I. M., Knudsen L. M., Kerndrup G. B., Lodahl M., Johnsen H. E., Kuehl M., Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica 2010 95 10 1730 1737 2-s2.0-77957761400 10.3324/haematol.2010. 024778
24. Landgren O., Kyle R. A., Pfeiffer R. M., Katzmann J. A., Caporaso N. E., Hayes R. B., Dispenzieri A., Kumar S., Clark R. J., Baris D., Hoover R., Rajkumar S. V., Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009 113 22 5412 5417 2-s2.0-67049162188 10.1182/blood-2008-12-194241
25. Altieri A., Chen B., Bermejo J. L., Castro F., Hemminki K., Familial risks and temporal incidence trends of multiple myeloma. European Journal of Cancer 2006 42 11 1661 1670 2-s2.0-33746364172 10.1016/j.ejca.2005.11.033 (Pubitemid 44118762)
26. Broderick P., Chubb D., Johnson D. C., Weinhold N., Försti A., Lloyd A., Olver B., Ma Y. P., Dobbins S. E., Walker B. A., Davies F. E., Gregory W. A., Child J. A., Ross F. M., Jackson G. H., Neben K., Jauch A., Hoffmann P., Mühleisen T. W., Nöthen M. M., Moebus S., Tomlinson I. P., Goldschmidt H., Hemminki K., Morgan G. J., Houlston R. S., Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nature Genetics 2012 44 1 58 61 2-s2.0-84655166569 10.1038/ng.993
27. Zhan F., Huang Y., Colla S., Stewart J. P., Hanamura I., Gupta S., Epstein J., Yaccoby S., Sawyer J., Burington B., Anaissie E., Hollmig K., Pineda-Roman M., Tricot G., Van Rhee F., Walker R., Zangari M., Crowley J., Barlogie B., Shaughnessy J. D. Jr., The molecular classification of multiple myeloma. Blood 2006 108 6 2020 2028 2-s2.0-33745779502 10.1182/blood-2005-11- 013458 (Pubitemid 44395016)
28. Keats J. J., Reiman T., Maxwell C. A., Taylor B. J., Larratt L. M., Mant M. J., Belch A. R., Pilarski L. M., In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003 101 4 1520 1529 2-s2.0-0037441747 10.1182/blood-2002-06-1675 (Pubitemid 36182529)
29. Fonseca R., Blood E., Rue M., Harrington D., Oken M. M., Kyle R. A., Dewald G. W., Van Ness B., Van Wier S. A., Henderson K. J., Bailey R. J., Greipp P. R., Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003 101 11 4569 4575 2-s2.0-0038142356 10.1182/blood-2002-10- 3017 (Pubitemid 36857829)
30. Chang H., Sloan S., Li D., Zhuang L., Yi Q.-L., Chen C. I., Reece D., Chun K., Stewart A. K., The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. British Journal of Haematology 2004 125 1 64 68 2-s2.0-1842557964 10.1111/j.1365-2141.2004.04867.x (Pubitemid 38453279)
31. Chesi M., Nardini E., Lim R. S. C., Smith K. D., Michael Kuehl W., Bergsagel P. L., The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998 92 9 3025 3034 2-s2.0-0032212243 (Pubitemid 28492306)
32. Santra M., Zhan F., Tian E., Barlogie B., Shaughnessy Jr. J., A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003 101 6 2374 2376 2-s2.0-0037443417 10.1182/blood-2002-09-2801 (Pubitemid 36302083)
33. Martinez-Garcia E., Popovic R., Min D.-J., Sweet S. M. M., Thomas P. M., Zamdborg L., Heffner A., Will C., Lamy L., Staudt L. M., Levens D. L., Kelleher N. L., Licht J. D., The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011 117 1 211 220 2-s2.0-78650978001 10.1182/blood-2010-07-298349
34. Pei H., Zhang L., Luo K., Qin Y., Chesi M., Fei F., Bergsagel P. L., Wang L., You Z., Lou Z., MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011 470 7332 124 128 2-s2.0-79551665780 10.1038/nature09658
35. San Miguel J. F., Schlag R., Khuageva N. K., Dimopoulos M. A., Shpilberg O., Kropff M., Spicka I., Petrucci M. T., Palumbo A., Samoilova O. S., Dmoszynska A., Abdulkadyrov K. M., Schots R., Jiang B., Mateos M.-V., Anderson K. C., Esseltine D. L., Liu K., Cakana A., Van De Velde H., Richardson P. G., Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. The New England Journal of Medicine 2008 359 9 906 917 2-s2.0-50449086728 10.1056/NEJMoa0801479
36. Avet-Loiseau H., Leleu X., Roussel M., Moreau P., Guerin-Charbonnel C., Caillot D., Marit G., Benboubker L., Voillat L., Mathiot C., Kolb B., Macro M., Campion L., Wetterwald M., Stoppa A.-M., Hulin C., Facon T., Attal M., Minvielle S., Harousseau J.-L., Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). Journal of Clinical Oncology 2010 28 30 4630 4634 2-s2.0-78049501226 10.1200/JCO.2010.28.3945
37. Kyle R. A., Child J. A., Anderson K., Barlogie B., Bataille R., Bensinger W., Bladé J., Boccadoro M., Dalton W., Dimopoulos M., Djulbegovic B., Drayson M., Durie B., Facon T., Fonseca R., Gahrton G., Greipp P., Harousseau J. L., Harrington D., Hussein M., Joshua D., Ludwig H., Morgan G., Oken M., Powles R., Richardson P., Roodman D., San Miguel J., Shimizu K., Shustik C., Sirohi B., Sonneveld P., Tricot G., Turesson I., Van Ness B., Vesole D., Weber D., Westin J., Wheatley K., Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology 2003 121 5 749 757 2-s2.0-0038509089 10.1046/j.1365-2141.2003.04355.x (Pubitemid 36718191)
38. Shaughnessy Jr. J., Gabrea A., Qi Y., Brents L., Zhan F., Tian E., Sawyer J., Barlogie B., Leif Bergsagel P., Kuehl M., Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001 98 1 217 223 2-s2.0-0035412392 10.1182/blood.V98.1.217
39. Chesi M., Bergsagel P. L., Brents L. A., Smith C. M., Gerhard D. S., Kuehl W. M., Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 1996 88 2 674 681 2-s2.0-0029978550 (Pubitemid 26240399)
40. Baughn L. B., di Liberto M., Wu K., Toogood P. L., Louie T., Gottschalk R., Niesvizky R., Cho H., Ely S., Moore M. A. S., Chen-Kiang S., A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Research 2006 66 15 7661 7667 2-s2.0-33747872306 10.1158/0008-5472.CAN- 06-1098 (Pubitemid 44289224)
41. Mao X., Cao B., Wood T. E., Hurren R., Tong J., Wang X., Wang W., Li J., Jin Y., Sun W., Spagnuolo P. A., MacLean N., Moran M. F., Datti A., Wrana J., Batey R. A., Schimmer A. D., A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood 2011 117 6 1986 1997 2-s2.0-79951474743 10.1182/blood-2010-05-284810
42. Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., Leyvraz S., Michallet M., Yakoub-Agha I., Garderet L., Marit G., Michaux L., Voillat L., Renaud M., Grosbois B., Guillerm G., Benboubker L., Monconduit M., Thieblemont C., Casassus P., Caillot D., Stoppa A.-M., Sotto J.-J., Wetterwald M., Dumontet C., Fuzibet J.-G., Azais I., Dorvaux V., Zandecki M., Bataille R., Minvielle S., Harousseau J.-L., Facon T., Mathiot C., Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007 109 8 3489 3495 2-s2.0-33847378314 10.1182/blood-2006-08-040410 (Pubitemid 46572539)
43. Hurt E. M., Wiestner A., Rosenwald A., Shaffer A. L., Campo E., Grogan T., Bergsagel P. L., Kuehl W. M., Staudt L. M., Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004 5 2 191 199 2-s2.0-1442285889 10.1016/S1535-6108(04)00019-4 (Pubitemid 38283804)
44. Ross F. M., Ibrahim A. H., Vilain-Holmes A., Winfield M. O., Chiecchio L., Protheroe R. K. M., Strike P., Gunasekera J. L., Jones A., Harrison C. J., Morgan G. J., Cross N. C. P., Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 2005 19 9 1634 1642 2-s2.0-26944484104 10.1038/sj.leu.2403857 (Pubitemid 43090409)
45. Avet-Loiseau H., Malard F., Campion L., Magrangeas F., Sebban C., Lioure B., Decaux O., Lamy T., Legros L., Fuzibet J.-G., Michallet M., Corront B., Lenain P., Hulin C., Mathiot C., Attal M., Facon T., Harousseau J.-L., Minvielle S., Moreau P., Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 2011 117 6 2009 2011 2-s2.0-79951504474 10.1182/blood-2010-07-295105
46. Ross F. M., Chiecchio L., Dagrada G., Protheroe R. K. M., Stockley D. M., Harrison C. J., Cross N. C., Szubert A. J., Drayson M. T., Morgan G. J., The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 2010 95 7 1221 1225 2-s2.0-77954516403 10.3324/haematol.2009. 016329
47. Dib A., Gabrea A., Glebov O. K., Bergsagel P. L., Kuehl W. M., Characterization of MYC translocations in multiple myeloma cell lines. Journal of the National Cancer Institute 2008 39 25 31 2-s2.0-52149094341 10.1093/jncimonographs/lgn011
48. Avet-Loiseau H., Gerson F., Magrangeas F., Minvielle S., Harousseau J.-L., Bataille R., Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001 98 10 3082 3086 2-s2.0-0035892119 10.1182/blood.V98.10.3082
49. Greipp P. R., San Miguel J., Durie B. G., International staging system for multiple myeloma. Journal of Clinical Oncology 2005 23 15 3412 3420
50. Gabrea A., Martelli M. L., Qi Y., Roschke A., Barlogie B., Shaughnessy J. D. Jr., Sawyer J. R., Kuehl W. M., Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes and Cancer 2008 47 7 573 590 2-s2.0-44349090331 10.1002/gcc.20563 (Pubitemid 351748344)
51. Chesi M., Robbiani D. F., Sebag M., Chng W. J., Affer M., Tiedemann R., Valdez R., Palmer S. E., Haas S. S., Stewart A. K., Fonseca R., Kremer R., Cattoretti G., Bergsagel P. L., AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008 13 2 167 180 2-s2.0-38549131395 10.1016/j.ccr.2008.01.007 (Pubitemid 351163163)
52. Avet-Loiseau H., Li C., Magrangeas F., Gouraud W., Charbonnel C., Harousseau J.-L., Attal M., Marit G., Mathiot C., Facon T., Moreau P., Anderson K. C., Campion L., Munshi N. C., Minvielle S., Prognostic significance of copy-number alterations in multiple myeloma. Journal of Clinical Oncology 2009 27 27 4585 4590 2-s2.0-74549190701 10.1200/JCO.2008.20.6136
53. Onodera N., McCabe N. R., Rubin C. M., Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. Blood 1992 80 1 203 208 2-s2.0-0026748638
54. Chng W. J., Kumar S., VanWier S., Ahmann G., Price-Troska T., Henderson K., Chung T.-H., Kim S., Mulligan G., Bryant B., Carpten J., Gertz M., Rajkumar S. V., Lacy M., Dispenzieri A., Kyle R., Greipp P., Bergsagel P. L., Fonseca R., Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Research 2007 67 7 2982 2989 2-s2.0-34248201056 10.1158/0008-5472.CAN-06-4046 (Pubitemid 46724834)
55. Agnelli L., Bicciato S., Mattioli M., Fabris S., Infini D., Verdelli D., Baldini L., Morabito F., Callea V., Lombardi L., Neri A., Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. Journal of Clinical Oncology 2005 23 29 7296 7306 2-s2.0-33644680752 10.1200/JCO.2005.01.3870 (Pubitemid 46202343)
56. Boyd K. D., Ross F. M., Chiecchio L., Dagrada G. P., Konn Z. J., Tapper W. J., Walker B. A., Wardell C. P., Gregory W. M., Szubert A. J., Bell S. E., Child J. A., Jackson G. H., Davies F. E., Morgan G. J., A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012 26 2 349 355 2-s2.0-84856706335 10.1038/leu.2011.204
57. Walker B. A., Leone P. E., Chiecchio L., Dickens N. J., Jenner M. W., Boyd K. D., Johnson D. C., Gonzalez D., Dagrada G. P., Protheroe R. K. M., Konn Z. J., Stockley D. M., Gregory W. M., Davies F. E., Ross F. M., Morgan G. J., A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010 116 15 e56 e65 2-s2.0-77957949804 10.1182/blood-2010-04-279596
58. Chang H., Qi X., Jiang A., Xu W., Young T., Reece D., 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplantation 2010 45 1 117 121 2-s2.0-75149176289 10.1038/bmt.2009.107
59. Fonseca R., Bergsagel P. L., Drach J., Shaughnessy J., Gutierrez N., Stewart A. K., Morgan G., Van Ness B., Chesi M., Minvielle S., Neri A., Barlogie B., Kuehl W. M., Liebisch P., Davies F., Chen-Kiang S., Durie B. G., Carrasco R., Sezer O., Reiman T., Pilarski L., Avet-Loiseau H., International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009 23 12 2210 2221 2-s2.0-74049162897
60. Shaughnessy J., Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005 10 supplement 1 117 126 2-s2.0-29244455863 10.1080/10245330512331390140 (Pubitemid 41829514)
61. Shaughnessy J. D. Jr., Zhan F., Burington B. E., Huang Y., Colla S., Hanamura I., Stewart J. P., Kordsmeier B., Randolph C., Williams D. R., Xiao Y., Xu H., Epstein J., Anaissie E., Krishna S. G., Cottler-Fox M., Hollmig K., Mohiuddin A., Pineda-Roman M., Tricot G., Van Rhee F., Sawyer J., Alsayed Y., Walker R., Zangari M., Crowley J., Barlogie B., Avalidated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007 109 6 2276 2284 2-s2.0-33947217497 10.1182/blood-2006-07-038430 (Pubitemid 46425864)
62. Shi L., Wang S., Zangari M., Xu H., Cao T. M., Xu C., Wu Y., Xiao F., Liu Y., Yang Y., Salama M., Li G., Tricot G., Zhan F., Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 2010 1 1 22 33 2-s2.0-80053270362
63. Boyd K. D., Ross F. M., Walker B. A., Wardell C. P., Tapper W. J., Chiecchio L., Dagrada G., Konn Z. J., Gregory W. M., Jackson G. H., Child J. A., Davies F. E., Morgan G. J., Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clinical Cancer Research 2011 17 24 7776 7784 2-s2.0-84055212016 10.1158/1078-0432.CCR-11-1791
64. Chang H., Jiang A., Qi C., Trieu Y., Chen C., Reece D., Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leukemia and Lymphoma 2010 51 11 2084 2091 2-s2.0-78649286046 10.3109/10428194.2010.524325
65. Leone P. E., Walker B. A., Jenner M. W., Chiecchio L., Dagrada G., Protheroe R. K. M., Johnson D. C., Dickens N. J., Brito J. L., Else M., Gonzalez D., Ross F. M., Chen-Kiang S., Davies F. E., Morgan G. J., Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clinical Cancer Research 2008 14 19 6033 6041 2-s2.0-58149166787 10.1158/1078-0432.CCR-08-0347
66. Fonseca R., Oken M. M., Harrington D., Bailey R. J., Van Wier S. A., Henderson K. J., Kay N. E., Van Ness B., Greipp P. R., Dewald G. W., Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001 15 6 981 986 2-s2.0-0034988904 10.1038/sj.leu.2402125 (Pubitemid 32529901)
67. Avet-Loiseau H., Li J.-Y., Morineau N., Facon T., Brigaudeau C., Harousseau J.-L., Grosbois B., Bataille R., Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. Blood 1999 94 8 2583 2589 2-s2.0-0032857034 (Pubitemid 29477286)
68. Chiecchio L., Protheroe R. K. M., Ibrahim A. H., Cheung K. L., Rudduck C., Dagrada G. P., Cabanas E. D., Parker T., Nightingale M., Wechalekar A., Orchard K. H., Harrison C. J., Cross N. C. P., Morgan G. J., Ross F. M., Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006 20 9 1610 1617 2-s2.0-33747611919 10.1038/sj.leu.2404304 (Pubitemid 44264105)
69. Avet-Loiseau H., Daviet A., Saunier S., Bataille R., Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. British Journal of Haematology 2000 111 4 1116 1117 2-s2.0-0034490134 10.1111/j.1365-2141.2000. 02488.x (Pubitemid 32104926)
70. Tricot G., Barlogie B., Jagannath S., Bracy D., Mattox S., Vesole D. H., Naucke S., Sawyer J. R., Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995 86 11 4250 4256 2-s2.0-0028880424
71. Pérez-Simón J. A., García-Sanz R., Tabernero M. D., Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998 91 9 3366 3371
72. Chng W. J., Santana-Dávila R., van Wier S. A., Ahmann G. J., Jalal S. M., Bergsagel P. L., Chesi M., Trendle M. C., Jacobus S., Blood E., Oken M. M., Henderson K., Kyle R. A., Gertz M. A., Lacy M. Q., Dispenzieri A., Greipp P. R., Fonseca R., Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006 20 5 807 813 2-s2.0-33646153077 10.1038/sj.leu.2404172
73. Gahrton G., Iacobelli S., Björkstrand B., Autologous/reduced- intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013 121 25 5055 5063
74. Tiedemann R. E., Gonzalez-Paz N., Kyle R. A., Santana-Davila R., Price-Troska T., Van Wier S. A., Chng W. J., Ketterling R. P., Gertz M. A., Henderson K., Greipp P. R., Dispenzieri A., Lacy M. Q., Rajkumar S. V., Bergsagel P. L., Stewart A. K., Fonseca R., Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008 22 5 1044 1052 2-s2.0-43749090639 10.1038/leu.2008.4 (Pubitemid 351689887)
75. Lodé L., Eveillard M., Trichet V., Soussi T., Wuillème S., Richebourg S., Magrangeas F., Ifrah N., Campion L., Traullé C., Guilhot F., Caillot D., Marit G., Mathiot C., Facon T., Attal M., Harousseau J.-L., Moreau P., Minvielle S., Avet-Loiseau H., Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 2010 95 11 1973 1976 2-s2.0-78149246124 10.3324/haematol.2010.023697
76. Drach J., Ackermann J., Fritz E., Krömer E., Schuster R., Gisslinger H., DeSantis M., Zojer N., Fiegl M., Roka S., Schuster J., Heinz R., Ludwig H., Huber H., Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998 92 3 802 809 2-s2.0-0032147210 (Pubitemid 28355463)
77. Jenner M. W., Leone P. E., Walker B. A., Ross F. M., Johnson D. C., Gonzalez D., Chiecchio L., Cabanas E. D., Dagrada G. P., Nightingale M., Protheroe R. K. M., Stockley D., Else M., Dickens N. J., Cross N. C. P., Davies F. E., Morgan G. J., Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 2007 110 9 3291 3300 2-s2.0-36148955443 10.1182/blood-2007-02-075069 (Pubitemid 350106322)
78. Annunziata C. M., Davis R. E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., Lenz G., Hanamura I., Wright G., Xiao W., Dave S., Hurt E. M., Tan B., Zhao H., Stephens O., Santra M., Williams D. R., Dang L., Barlogie B., Shaughnessy J. D. Jr., Kuehl W. M., Staudt L. M., Frequent engagement of the classical and alternative NF- B pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007 12 2 115 130 2-s2.0-34547562418 10.1016/j.ccr.2007.07.004 (Pubitemid 47199123)
79. Keats J. J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T., Ahmann G., Mancini C., Brents L. A., Kumar S., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M., Valdez R., Trent J., Stewart A. K., Carpten J., Bergsagel P. L., Promiscuous mutations activate the noncanonical NF- B pathway in multiple myeloma. Cancer Cell 2007 12 2 131 144 2-s2.0-34547660308 10.1016/j.ccr.2007.07.003 (Pubitemid 47208626)
80. Sutlu T., Alici E., Jansson M., Wallblom A., Dilber M. S., Gahrton G., Nahi H., The prognostic significance of 8p21 deletion in multiple myeloma. British Journal of Haematology 2009 144 2 266 268 2-s2.0-58149095084 10.1111/j.1365-2141.2008.07454.x
81. Neben K., Jauch A., Bertsch U., Heiss C., Hielscher T., Seckinger A., Mors T., Müller N. Z., Hillengass J., Raab M. S., Ho A. D., Hose D., Goldschmidt H., Combining information regarding chromosomal aberrations t(4;14) and del(17pl3) with the international staging system classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010 95 7 1150 1157 2-s2.0-77954477911 10.3324/haematol.2009.016436
82. Gmidène A., Saad A., Avet-Loiseau H., 8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma. Medical Oncology 2013 30 2 489
83. Gazitt Y., TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999 13 11 1817 1824 2-s2.0-0032717188 (Pubitemid 29535266)
84. Takeda K., Smyth M. J., Cretney E., Hayakawa Y., Kayagaki N., Yagita H., Okumura K., Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. Journal of Experimental Medicine 2002 195 2 161 169 2-s2.0-0037148518 10.1084/jem.20011171 (Pubitemid 34461260)
85. Liu H., Tamashiro S., Baritaki S., TRAF6 activation in multiple myeloma: a potential therapeutic target. Clinical Lymphoma Myeloma and Leukemia 2012 12 3 155 163
86. Chauhan D., Uchiyama H., Akbarali Y., Urashima M., Yamamoto K.-I., Libermann T. A., Anderson K. C., Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF- B. Blood 1996 87 3 1104 1112 2-s2.0-0030041147 (Pubitemid 26043538)
87. Tai Y.-T., Li X.-F., Breitkreutz I., Song W., Neri P., Catley L., Podar K., Hideshima T., Chauhan D., Raje N., Schlossman R., Richardson P., Munshi N. C., Anderson K. C., Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Research 2006 66 13 6675 6682 2-s2.0-33746122751 10.1158/0008-5472.CAN-06-0190 (Pubitemid 44085624)
88. Chng W. J., Gonzalez-Paz N., Price-Troska T., Jacobus S., Rajkumar S. V., Oken M. M., Kyle R. A., Henderson K. J., Van Wier S., Greipp P., Van Ness B., Fonseca R., Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008 22 12 2280 2284 2-s2.0-57849129292 10.1038/leu.2008.142
89. Rasmussen T., Kuehl M., Lodahl M., Johnsen H. E., Dahl I. M. S., Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005 105 1 317 323 2-s2.0-11144235574 10.1182/blood-2004-03-0833 (Pubitemid 40053099)
90. Tiacci E., Trifonov V., Schiavoni G., Holmes A., Kern W., Martelli M. P., Pucciarini A., Bigerna B., Pacini R., Wells V. A., Sportoletti P., Pettirossi V., Mannucci R., Elliott O., Liso A., Ambrosetti A., Pulsoni A., Forconi F., Trentin L., Semenzato G., Inghirami G., Capponi M., Di Raimondo F., Patti C., Arcaini L., Musto P., Pileri S., Haferlach C., Schnittger S., Pizzolo G., Foà R., Farinelli L., Haferlach T., Pasqualucci L., Rabadan R., Falini B., BRAF mutations in hairy-cell leukemia. The New England Journal of Medicine 2011 364 24 2305 2315 2-s2.0-79959293462 10.1056/NEJMoa1014209
91. Patrawala S., Puzanov I., Vemurafenib, (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncology 2012 8 5 509 523
92. Bharti A. C., Shishodia S., Reuben J. M., Weber D., Alexanian R., Raj-Vadhan S., Estrov Z., Talpaz M., Aggarwal B. B., Nuclear factor- B and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004 103 8 3175 3184 2-s2.0-1842579486 10.1182/blood-2003-06-2151 (Pubitemid 38451696)
93. Catlett-Falcone R., Landowski T. H., Oshiro M. M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernández-Luna J. L., Nuñez G., Dalton W. S., Jove R., Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999 10 1 105 115 2-s2.0-0032984589 10.1016/S1074-7613(00)80011-4 (Pubitemid 29077388)
94. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T., Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988 332 6159 83 85 2-s2.0-0023849455
95. Klein B., Zhang X.-G., Lu Z.-Y., Bataille R., Interleukin-6 in human multiple myeloma. Blood 1995 85 4 863 872 2-s2.0-0028921477
96. Tu Y., Renner S., Xu F.-H., Fleishman A., Taylor J., Weisz J., Vescio R., Rettig M., Berenson J., Krajewski S., Reed J. C., Lichtenstein A., BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Research 1998 58 2 256 262 2-s2.0-0031984216 (Pubitemid 28047064)
97. Bharti A. C., Donato N., Aggarwal B. B., Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. Journal of Immunology 2003 171 7 3863 3871 2-s2.0-0141955061 (Pubitemid 37254592)
98. Amit-Vazina M., Shishodia S., Harris D., Van Q., Wang M., Weber D., Alexanian R., Talpaz M., Aggarwal B. B., Estrov Z., Atiprimod blocks STAT3
99. de Vos J., Jourdan M., Tarte K., Jasmin C., Klein B., JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. British Journal of Haematology 2000 109 4 823 828 2-s2.0-0033861096 10.1046/j.1365-2141.2000.02127.x (Pubitemid 30609763)
100. Alas S., Bonavida B., Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clinical Cancer Research 2003 9 1 316 326 2-s2.0-0037236924 (Pubitemid 36109748)
101. Aronson L., Davenport E., Giuntoli S., Autophagy is a key myeloma survival pathway that can be manipulated therapeutically to enhance apoptosis. ASH Annula Meeting Abstracts 2010 116 21 4083
102. Boyd K. D., Walker B. A., Wardell C. P., Ross F. M., Gregory W. M., Davies F. E., Morgan G. J., High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leukemia and Lymphoma 2010 51 11 2126 2129 2-s2.0-78649240797 10.3109/10428194.2010.509893
103. Dib A., Barlogie B., Shaughnessy J. D. Jr., Kuehl W. M., Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 2007 109 3 1337 1338 2-s2.0-33846878522 10.1182/blood-2006-09-049510 (Pubitemid 46220692)
104. Neri P., Ren L., Gratton K., Stebner E., Johnson J., Klimowicz A., Duggan P., Tassone P., Mansoor A., Stewart D. A., Lonial S., Boise L. H., Bahlis N. J., Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood 2011 118 24 6368 6379 2-s2.0-83455195500 10.1182/blood-2011-06-363911
105. Decaux O., Lodé L., Magrangeas F., Charbonnel C., Gouraud W., Jézéquel P., Attal M., Harousseau J.-L., Moreau P., Bataille R., Campion L., Avet-Loiseau H., Minvielle S., Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. Journal of Clinical Oncology 2008 26 29 4798 4805 2-s2.0-54249092519 10.1200/JCO.2007.13.8545
106. Gibson B. A., Kraus W. L., New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nature Reviews Molecular Cell Biology 2012 13 7 411 424
107. Kummar S., Chen A., Parchment R. E., Kinders R. J., Ji J., Tomaszewski J. E., Doroshow J. H., Advances in using PARP inhibitors to treat cancer. BMC Medicine 2012 10, article 25 2-s2.0-84857936584 10.1186/1741-7015-10-25
108. Dziembowski A., Lorentzen E., Conti E., Séraphin B., A single subunit, Dis3, is essentially responsible for yeast exosome core activity. Nature Structural and Molecular Biology 2007 14 1 15 22 2-s2.0-33846068920 10.1038/nsmb1184 (Pubitemid 46067418)
109. Schmid M., Jensen T. H., The exosome: a multipurpose RNA-decay machine. Trends in Biochemical Sciences 2008 33 10 501 510 2-s2.0-52949089292 10.1016/j.tibs.2008.07.003
110. Schneider C., Anderson J. T., Tollervey D., The exosome subunit Rrp44 Plays a direct role in RNA substrate recognition. Molecular Cell 2007 27 2 324 331 2-s2.0-34447300418 10.1016/j.molcel.2007.06.006 (Pubitemid 47058304)
111. Barbas A., Matos R. G., Amblar M., López-Viñas E., Gomez-Puertas P., Arraiano C. M., Determination of key residues for catalysis and RNA cleavage specificity. One mutation turns RNase II Into a 'super-enzyme'. Journal of Biological Chemistry 2009 284 31 20486 20498 2-s2.0-68949127239 10.1074/jbc.M109.020693
112. Ibrahim H., Wilusz J., Wilusz C. J., RNA recognition by 3′-to-5′ exonucleases: the substrate perspective. Biochimica et Biophysica Acta 2008 1779 4 256 265 2-s2.0-41549107524 10.1016/j.bbagrm.2007.11. 004 (Pubitemid 351474486)
113. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R. J., Calne D. B., Stoessl A. J., Pfeiffer R. F., Patenge N., Carbajal I. C., Vieregge P., Asmus F., Müller-Myhsok B., Dickson D. W., Meitinger T., Strom T. M., Wszolek Z. K., Gasser T., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004 44 4 601 607 2-s2.0-8844233579 10.1016/j.neuron.2004.11.005 (Pubitemid 39531225)
114. Paisán-Ruíz C., Jain S., Evans E. W., Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004 44 4 595 600 (Pubitemid 39531224)
115. Masciarelli S., Fra A. M., Pengo N., Bertolotti M., Cenci S., Fagioli C., Ron D., Hendershot L. M., Sitia R., CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. Molecular Immunology 2010 47 6 1356 1365 2-s2.0-76949099567 10.1016/j.molimm.2009.12.003
116. Cenci S., Sitia R., Managing and exploiting stress in the antibody factory. FEBS Letters 2007 581 19 3652 3657 2-s2.0-34447550255 10.1016/j.febslet.2007.04.031 (Pubitemid 47081003)
117. Carrasco D. R., Sukhdeo K., Protopopova M., Sinha R., Enos M., Carrasco D., Zheng M., Mani M., Henderson J., Pinkus G. S., Munshi N., Horner J., Ivanova E. V., Protopopov A., Anderson K. C., Tonon G., DePinho R. A., The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007 11 4 349 360 2-s2.0-34047136169 10.1016/j.ccr.2007.02.015 (Pubitemid 46518314)
118. Reimold A. M., Iwakoshi N. N., Manis J., Vallabhajosyula P., Szomolanyi-Tsuda E., Gravallese E. M., Friend D., Grusby M. J., Alt F., Glimcher L. H., Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001 412 6844 300 307 2-s2.0-0035913294 10.1038/35085509 (Pubitemid 32691837)
119. Bagratuni T., Wu P., Gonzalez de Castro D., Davenport E. L., Dickens N. J., Walker B. A., Boyd K., Johnson D. C., Gregory W., Morgan G. J., Davies F. E., XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood 2010 116 2 250 253 2-s2.0-77955486614 10.1182/blood-2010-01-263236
120. Shaffer A. L., Emre N. C. T., Lamy L., Ngo V. N., Wright G., Xiao W., Powell J., Dave S., Yu X., Zhao H., Zeng Y., Chen B., Epstein J., Staudt L. M., IRF4 addiction in multiple myeloma. Nature 2008 454 7201 226 231 2-s2.0-47049120726 10.1038/nature07064 (Pubitemid 351969894)
121. Mandelbaum J., Bhagat G., Tang H., Mo T., Brahmachary M., Shen Q., Chadburn A., Rajewsky K., Tarakhovsky A., Pasqualucci L., Dalla-Favera R., BLIMP1 Is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010 18 6 568 579 2-s2.0-78650004237 10.1016/j.ccr.2010.10.030
122. Wu P., Walker B. A., Brewer D., Gregory W. M., Ashcroft J., Ross F. M., Jackson G. H., Child A. J., Davies F. E., Morgan G. J., A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clinical Cancer Research 2011 17 19 6347 6355 2-s2.0-80053537013 10.1158/1078-0432.CCR-11-0994
123. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., Shaughnessy J. D. Jr., The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine 2003 349 26 2483 2494 2-s2.0-0346363760 10.1056/NEJMoa030847 (Pubitemid 38010074)
124. Qiang Y.-W., Chen Y., Stephens O., Brown N., Chen B., Epstein J., Barlogie B., Shaughnessy J. D. Jr., Myeloma-derived dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008 112 1 196 207 2-s2.0-47249140444 10.1182/blood-2008-01-132134
125. Fulciniti M., Tassone P., Hideshima T., Vallet S., Nanjappa P., Ettenberg S. A., Shen Z., Patel N., Tai Y.-T., Chauhan D., Mitsiades C., Prabhala R., Raje N., Anderson K. C., Stover D. R., Munshi N. C., Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009 114 2 371 379 2-s2.0-67650431302 10.1182/blood-2008-11-191577
126. Robbiani D. F., Chesi M., Bergsagel P. L., Bone lesions in molecular subtypes of multiple myeloma. The New England Journal of Medicine 2004 351 2 197 198 2-s2.0-3042805477 10.1056/NEJM200407083510223 (Pubitemid 38886662)
127. Morgan G. J., Davies F. E., Gregory W. M., Cocks K., Bell S. E., Szubert A. J., Navarro-Coy N., Drayson M. T., Owen R. G., Feyler S., Ashcroft A. J., Ross F., Byrne J., Roddie H., Rudin C., Cook G., Jackson G. H., Child J. A., First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. The Lancet 2010 376 9757 1989 1999 2-s2.0-78650174738 10.1016/S0140-6736(10)62051-X
128. Sawan C., Vaissière T., Murr R., Herceg Z., Epigenetic drivers and genetic passengers on the road to cancer. Mutation Research 2008 642 1-2 1 13 2-s2.0-49649128638 10.1016/j.mrfmmm.2008.03.002
129. Walker B. A., Wardell C. P., Chiecchio L., Smith E. M., Boyd K. D., Neri A., Davies F. E., Ross F. M., Morgan G. J., Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011 117 2 553 562 2-s2.0-78751508049 10.1182/blood-2010-04-279539
130. Brito J. L. R., Walker B., Jenner M., Dickens N. J., Brown N. J. M., Ross F. M., Avramidou A., Irving J. A. E., Gonzalez D., Davies F. E., Morgan G. J., MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica 2009 94 1 78 86 2-s2.0-58149232433 10.3324/haematol.13426
131. Rouhi A., Mager D. L., Humphries R. K., Kuchenbauer F., MiRNAs, epigenetics, and cancer. Mammalian Genome 2008 19 7-8 517 525 2-s2.0-56949091982 10.1007/s00335-008-9133-x
132. Zhoua Y., Chena L., Barlogiea B., Stephensa O., Wua X., Williamsa D. R., Van Rheea F., Naira B., Waheeda S., Pineda-Romana M., Alsayeda Y., Anaissiea E., Shaughnessy J. D. Jr., High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proceedings of the National Academy of Sciences of the United States of America 2010 107 17 7904 7909 2-s2.0-77952340609 10.1073/pnas.0908441107
133. Lionetti M., Biasiolo M., Agnelli L., Todoerti K., Mosca L., Fabris S., Sales G., Deliliers G. L., Bicciato S., Lombardi L., Bortoluzzi S., Neri A., Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009 114 25 e20 e26 2-s2.0-73949101367 10.1182/blood-2009-08-237495
134. Gutiérrez N. C., Sarasquete M. E., Misiewicz-Krzeminska I., Delgado M., De Las Rivas J., Ticona F. V., Fermĩán E., Martín-Jiménez P., Chillón C., Risuo A., Hernández J. M., García-Sanz R., González M., San Miguel J. F., Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010 24 3 629 637 2-s2.0-77949423427 10.1038/leu.2009.274
135. Pichiorri F., Suh S.-S., Rocci A., De Luca L., Taccioli C., Santhanam R., Zhou W., Benson D. M., Hofmainster C., Alder H., Garofalo M., Di Leva G., Volinia S., Lin H.-J., Perrotti D., Kuehl M., Aqeilan R. I., Palumbo A., Croce C. M., Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010 18 4 367 381 2-s2.0-77957936826 10.1016/j.ccr.2010.09.005
136. Pichiorri F., Suh S.-S., Ladetto M., Kuehl M., Palumbo T., Drandi D., Taccioli C., Zanesi N., Alder H., Hagan J. P., Munker R., Volinia S., Boccadoro M., Garzon R., Palumbo A., Aqeilan R. I., Croce C. M., MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America 2008 105 35 12885 12890 2-s2.0-51349093465 10.1073/pnas.0806202105
137. Chang T.-C., Yu D., Lee Y.-S., Wentzel E. A., Arking D. E., West K. M., Dang C. V., Thomas-Tikhonenko A., Mendell J. T., Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genetics 2008 40 1 43 50 2-s2.0-37549008310 10.1038/ng.2007.30